148 related articles for article (PubMed ID: 15353339)
1. Soluble interleukin-2 receptor in cancer.
Murakami S
Front Biosci; 2004 Sep; 9():3085-90. PubMed ID: 15353339
[TBL] [Abstract][Full Text] [Related]
2. Changes in the levels of serum-soluble interleukin-2 receptor after surgical stress.
Murakami S; Sakata H; Tsuji Y; Okubo K; Takahashi T; Kikuchi M; Hirayama R
Surg Today; 2003; 33(8):565-70. PubMed ID: 12884092
[TBL] [Abstract][Full Text] [Related]
3. Serum interleukin 2 and soluble interleukin 2 receptor in chronic active hepatitis C: effect of interferon therapy.
Simsek H; Kadayifci A
J Int Med Res; 1996; 24(3):239-45. PubMed ID: 8725984
[TBL] [Abstract][Full Text] [Related]
4. The role of tumor-associated macrophages on serum soluble IL-2R levels in B-cell lymphomas.
Sakai A; Yoshida N
J Clin Exp Hematop; 2014; 54(1):49-57. PubMed ID: 24942946
[TBL] [Abstract][Full Text] [Related]
5. Analysis of interleukin-2/interleukin-2 receptor system in advanced non-small-cell lung cancer.
De Vita F; Turitto G; di Grazia M; Frattolillo A; Catalano G
Tumori; 1998; 84(1):33-8. PubMed ID: 9619711
[TBL] [Abstract][Full Text] [Related]
6. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
8. A novel role of metalloproteinase in cancer-mediated immunosuppression.
Sheu BC; Hsu SM; Ho HN; Lien HC; Huang SC; Lin RH
Cancer Res; 2001 Jan; 61(1):237-42. PubMed ID: 11196168
[TBL] [Abstract][Full Text] [Related]
9. Measurement of the concentration of serum soluble interleukin-2 receptor alpha chain in dogs with lymphoma.
Mizutani N; Goto-Koshino Y; Kurata K; Fujiwara-Igarashi A; Sakaguchi M; Asada M; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2020 Jul; 225():110054. PubMed ID: 32434088
[TBL] [Abstract][Full Text] [Related]
10. Serum-soluble IL-2 receptor and IL-6 levels in patients with melanoma.
Boyano MD; García-Vázquez MD; Gardeazabal J; García de Galdeano A; Smith-Zubiaga I; Cañavate ML; Raton JA; Bilbao I; Díaz-Pérez JL
Oncology; 1997; 54(5):400-6. PubMed ID: 9260602
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of serum soluble T cell regulatory molecules in clear cell renal cell carcinoma.
Masuda A; Arai K; Nishihara D; Mizuno T; Yuki H; Kambara T; Betsunoh H; Abe H; Yashi M; Fukabori Y; Yoshida K; Kamai T
Biomed Res Int; 2014; 2014():396064. PubMed ID: 25089268
[TBL] [Abstract][Full Text] [Related]
12. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
Elg SA; Hill RB; Heldman L; Ramakrishnan S
Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
[TBL] [Abstract][Full Text] [Related]
13. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
[TBL] [Abstract][Full Text] [Related]
14. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
15. Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.
Kanazawa S; Yamaguchi K; Kinoshita Y; Komiyama Y; Muramatsu M; Nomura S
J Cancer Res Clin Oncol; 2006 Nov; 132(11):719-25. PubMed ID: 16835747
[TBL] [Abstract][Full Text] [Related]
16. [The role of serum soluble interleukin 2 receptor (sIL-2R) levels in patients with renal cell carcinoma].
Akiyama K; Tsuji M; Kurokawa Y; Yokota K; Kojima K; Naruo S; Kanayana HO; Kagawa S
Nihon Hinyokika Gakkai Zasshi; 1997 Apr; 88(4):473-8. PubMed ID: 9155114
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors in patients with solid tumors are not correlated.
Lissoni P; Rizzo V; Barni S; Rescaldani R; Rovelli F; Biondi A; Archili C; Frigerio F; Tancini G
Int J Biol Markers; 1989; 4(3):170-3. PubMed ID: 2614085
[TBL] [Abstract][Full Text] [Related]
18. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms.
Bodey B; Psenko V; Lipsey AL; Kaiser HE
Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612
[TBL] [Abstract][Full Text] [Related]
19. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.
Naumnik W; Chyczewska E
Folia Histochem Cytobiol; 2001; 39 Suppl 2():185-6. PubMed ID: 11820599
[TBL] [Abstract][Full Text] [Related]
20. Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with solid tumors.
Orditura M; De Vita F; Roscigno A; Auriemma A; Infusino S; Catalano G
Int J Mol Med; 1998 Jul; 2(1):75-9. PubMed ID: 9854147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
